reduced quality of life and risk of death," commented Nicole Verdun, director of the Office of Therapeutic Products in the FSA's Centre for Biologics Evaluation and Research (CBER). Ryoncil's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback